Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per shar

Event · Offering · proposed
Instrument
New Warrants
Shares
406,198 shares
Price per share
$7.50 per share

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 19, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GCTK
Neutral
high confidence
Mentioned
$GCTK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GCTKNeutralMed
01

Why it matters

The agreement may affect short‑term share price due to dilution concerns, but the conditional nature of the warrants limits immediate impact.

02

Market read

Primary disclosure of a material definitive agreement for a micro‑cap; modest trading relevance.

03

What to watch

The 9.99% ownership limit and floor price may restrict large holders from exercising, mitigating dilution.

Relevance 6/10Novelty 7/10Timing: post‑filing Oct 19 2026

Background

Glucotrack is a clinical‑stage company developing glucose monitoring technology. The 8‑K details a waiver of prior issuance restrictions and the grant of new warrants.

Company-level read

Ticker impact

$GCTKNeutralHigh confidence
Context

Glucotrack filed an 8‑K reporting a waiver agreement and issuance of new warrants for 406,198 shares.

Expected impact

likely modest downward pressure as the market prices potential dilution

Evidence & confidence

The filing is the first public disclosure of the agreement; investors will assess dilution risk and the conditional nature of the warrants.

Market effects

Limited to biotech/health‑tech sector; no broad sector impact.

U.S. micro‑cap market only.

Low

Counterpoint

If the warrants are exercised at $7.50, they could provide capital and support the share price.

Key entities

  • Glucotrack, Inc.

    Issuer of the new warrants

  • Erik Emerson

    CEO who signed the filing

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.